Section
This review synthesizes key findings evaluating olorofim’s clinical effectiveness and safety in patients with refractory disseminated coccidioidomycosis, emphasizing its potential role amid limited treatment options.
A translational study combining human heart tissue, CRISPR mouse models, and multi-omics reveals that loss of the ACL enzyme alters cardiac metabolism, promoting left ventricular dysfunction; restoring citrate flux via IDH1 deletion improves function in mice.
This analysis of the SOUL trial shows oral semaglutide reduces major cardiovascular events, with greater benefits linked to higher baseline HbA1c and larger HbA1c reductions, while BMI changes did not significantly affect outcomes.
GLP-1 receptor agonists significantly reduce atherosclerosis progression, inflammatory biomarkers, and cardiovascular events independent of glycaemic control and obesity status, evidenced by robust preclinical and large-scale clinical data.
Medically tailored groceries modestly improve HbA1c and significantly enhance food and nutrition security among Medicaid-insured adults with type 2 diabetes, supporting ‘Food Is Medicine’ strategies in chronic disease management
This study introduces and validates a simplified machine learning-based equation for estimating LDL cholesterol, showing comparable accuracy to the original Martin-Hopkins method and improved ease of use.
This article reviews recent advances in the medical management of peripheral artery disease, emphasizing comprehensive risk factor control, novel pharmacotherapies, and individualized approaches to improve cardiovascular and limb outcomes i
A prospective multicenter study demonstrates that AI-driven virtual native enhancement (VNE) MRI can accurately detect and quantify myocardial scars without contrast agents, potentially reducing the need for gadolinium-based imaging in clin
The ESRA trial demonstrates that riociguat is safe and effectively reduces pulmonary vascular resistance in early pulmonary vascular disease, though secondary benefits remain unproven in this early-stage, mostly connective tissue disease-as
This study reveals significant gaps in discharge communication, self-care education, medication management, and follow-up coordination during skilled nursing facility-to-home transitions after heart failure hospitalization, highlighting the
This study compares the predictive value of non-HDL cholesterol and apolipoprotein B for atherosclerotic cardiovascular disease risk in individuals not on lipid-lowering medication.
Recent decades saw increased anticoagulant use and reduced stroke risk in elderly AF patients, especially with DOACs, but bleeding risks rise notably in very elderly patients, highlighting tailored management needs.
This study assesses how coronary artery calcium (CAC) scoring refines statin eligibility using the new PREVENT risk calculator, emphasizing its value in borderline risk patients and cautioning against withholding statins solely for CAC 0 in
BACH1 stabilization under hypoxia promotes pulmonary hypertension by enhancing TGFBR2/SMAD pathway activity in pulmonary artery smooth muscle cells, suggesting BACH1 as a promising therapeutic target for PH.
This study reveals that specific gene mutations and cardiovascular risk factors significantly influence prognosis and thrombotic risk in triple-negative essential thrombocythemia, highlighting the importance of molecular profiling for perso
HERZCHECK demonstrates that mobile, telemedically supervised cardiac MRI enables early detection of subclinical preheart failure in at-risk individuals with cardiovascular risk factors in rural areas, identifying disease nearly seven years
A comprehensive nationwide study reveals that maternal diabetes during pregnancy, particularly pregestational diabetes, significantly increases offspring’s risk of early-onset cardiovascular diseases, mediated partly by perinatal comp
This study from two Spanish cohorts explores how moderate wine consumption within a Mediterranean diet impacts cardiovascular disease and mortality, suggesting modest benefits but advising cautious interpretation.
The ORBITA-CTO multicenter, randomized, placebo-controlled trial demonstrates that PCI significantly improves angina symptoms and quality of life in patients with single-vessel CTO without bystander disease, compared to placebo.
This study reveals that bisphenol F exposure aggravates cardiomyopathy under hemodynamic stress through gut microbiota metabolism, highlighting a novel gut-heart axis involving N-acetylputrescine and potential therapeutic targets.
